{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:42:37Z","timestamp":1785526957507,"version":"3.56.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002332","name":"Semmelweis University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prenylation (geranylgeranylation or farnesylation) plays an important role in the regulation of RAS proteins. This observation led to development of farnesyltransferase inhibitors (FTI) which were extensively tested in clinical studies of various cancer types. Unfortunately, these studies failed and the development of these drugs stalled.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main body<\/jats:title>\n                    <jats:p>The renaissance of FTIs started with the approval of lonafarnib in children\u2019s progeria syndromes and continued with the approval of tipifarnib in HRAS-mutant head and neck cancers. Although there are several trials running on various viral infections (HDV, RSV, SARS), their future in oncology is based on the novel preclinical findings that FTIs can potentiate the efficacy of novel KRAS inhibitors or other target therapies such as EGFR- or multikinase inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The \u201esecond chance\u201d for FTIs is here but the successful clinical implementation of FTIs can only be achieved if the design of the new clinical trials do not repeat mistakes of the past: application of these drugs without predictive markers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-026-08298-5","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T15:55:32Z","timestamp":1779983732000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Renaissance of farnesyltransferase inhibitors in cancer"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9183-0859","authenticated-orcid":false,"given":"J\u00f3zsef","family":"T\u00edm\u00e1r","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs","family":"Heged\u0171s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcell","family":"Baranyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"8298_CR1","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ccr.2005.04.005","volume":"7","author":"SM Sebti","year":"2005","unstructured":"Sebti SM. Protein farnesylation: implication for normal physiology, malignant transformation and cancer therapy. Cancer Cell. 2005;7:297\u2013300.","journal-title":"Cancer Cell"},{"key":"8298_CR2","unstructured":"Kamath A, Kamanna K. Prenylated proteins: structural diversity and functions. In: Modifications of Biomacromolecules, ed. Zhan X, Jabbari A, IntechOpen\/Chapters\/81508,2022."},{"key":"8298_CR3","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrm.2015.11","volume":"17","author":"M Wang","year":"2016","unstructured":"Wang M, Casey PJ. Protein prenylation: unique facts make their mark on biology. Nat Rev Mol Cell Biol. 2016;17:110\u201322.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8298_CR4","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1371\/journal.pcbi.0030066","volume":"3","author":"S Maurer-Stroh","year":"2007","unstructured":"Maurer-Stroh S, Koranda M, Benetka W, Schneider G, Sirota FL, Eisenhaber F. Towards complete set of farnesylated and geranylated proteins. Plos Comp Biology. 2007;3:634\u201348.","journal-title":"Plos Comp Biology"},{"key":"8298_CR5","doi-asserted-by":"crossref","unstructured":"Pan Y, Berkovska O, Marathe S, Mermelakas G, Gudoitye G, et al. Functional-proteomics-based investigation of cellular response to farnesyltransferase inhibition in lung cancer. iScience. 2025;28:111864.","DOI":"10.1016\/j.isci.2025.111864"},{"key":"8298_CR6","doi-asserted-by":"crossref","unstructured":"Kim JH, Hildebrandt ER, Sarkar A, Yeung W, Waldon LRA, et al. A comprehensive in vivo screen of yeast farnesyltransferase activityreveals broad reactivity across a majority of CXXX sequences. G3 (Bethesa). 2023;13:kad094.","DOI":"10.1093\/g3journal\/jkad094"},{"key":"8298_CR7","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s10555-020-09902-w","volume":"39","author":"M Baranyi","year":"2020","unstructured":"Baranyi M, Buday L, Heged\u0171s B. K-RAS prenylation as a potential anticancer target. Cancer Metast Rev. 2020;39:1127\u201341.","journal-title":"Cancer Metast Rev"},{"key":"8298_CR8","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s10555-020-09915-5","volume":"39","author":"J T\u00edm\u00e1r","year":"2020","unstructured":"T\u00edm\u00e1r J, Kashofer K. Molecular epidemiology and diagnostics of KRAS mutations in human cancer. Cancer Metastasis Rev. 2020;39:1029\u201338.","journal-title":"Cancer Metastasis Rev"},{"key":"8298_CR9","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1001\/jama.2022.12138","volume":"328","author":"R Chou","year":"2022","unstructured":"Chou R, Cantor A, Dana T, Wagner J, Azrah Y, et al. Statin for the primary prevention of cardiovascular disease in adults. JAMA. 2022;328:754\u201371.","journal-title":"JAMA"},{"key":"8298_CR10","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1093\/annonc\/mdg401","volume":"14","author":"D Santini","year":"2003","unstructured":"Santini D, Gentilucci UV, Vincenzi B, Picardi A, Vasaturo F, et al. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol. 2003;14:1468\u201376.","journal-title":"Ann Oncol"},{"key":"8298_CR11","doi-asserted-by":"crossref","unstructured":"D\u2019Oronzo S, Woods S, Brown JE. The use of bisphosphonates to treat skeletal complications in solid tumors. Bone. 2021;147:115907.","DOI":"10.1016\/j.bone.2021.115907"},{"key":"8298_CR12","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1021\/ja808285e","volume":"131","author":"Y Zhang","year":"2009","unstructured":"Zhang Y, Cao R, Yin F, Hudock MP, et al. Lipophylic bisphosphonates as dual farnesyl- geranylgeranyl disphosphate synthase inhibitors: an X-ray and NMR investigation. J Am Chem Soc. 2009;131:5153\u201362.","journal-title":"J Am Chem Soc"},{"key":"8298_CR13","doi-asserted-by":"crossref","unstructured":"Berndt N, Hamilton AD, Sebti SM. Targeting protein prenylation for cancer therapy. Nat Rev Cancer. 2011;11:775\u201391.","DOI":"10.1038\/nrc3151"},{"key":"8298_CR14","doi-asserted-by":"crossref","unstructured":"Smith A, Patel H, Chan S, Burrows F, Malik S. The next-generation farnesyltransferase inhibitor KO-2806 constrains compensatory signaling reactivation to deepen responses to KRASG12D inhibition. Mol Cancer Ther. 2023;22S:B023.","DOI":"10.1158\/1535-7163.TARG-23-B023"},{"key":"8298_CR15","doi-asserted-by":"crossref","unstructured":"Kazi A, Xiang S, Yang H et al. Dual farnesyl and geranyl transferase inhibitor thwarts mutant KRAS-driven patient derived pancreatic tumors. Clin Cancer Res. 2019;25:5984\u201396.","DOI":"10.1158\/1078-0432.CCR-18-3399"},{"key":"8298_CR16","doi-asserted-by":"publisher","first-page":"5424","DOI":"10.3390\/ijms23105424","volume":"23","author":"A Marchwicka","year":"2022","unstructured":"Marchwicka A, Kaminska D, Monirialamdari M, Blazewska K, Gendaszewska-Darmach E. Protein prenyltransferases and their inhibitors: structural and functional characterization. Int J Mol Sci. 2022;23:5424.","journal-title":"Int J Mol Sci"},{"key":"8298_CR17","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10549-013-2704-x","volume":"41","author":"E Andreopoulou","year":"2013","unstructured":"Andreopoulou E, Vigoda IS, Valero V, Hersman DL, Raptis G, et al. Phase-I-II study of the farnesyltransferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2\/neu negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma. Breast Cancer Res Treat. 2013;41:429\u201335.","journal-title":"Breast Cancer Res Treat"},{"key":"8298_CR18","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1093\/neuonc\/nou004","volume":"16","author":"B Widermann","year":"2014","unstructured":"Widermann B, Dombi E, Gillespie A, Wolters PL, Belasco J, et al. Phase 2 randomized felxible croissover double blinded placebo-controlled trial of the farnesytransferase inhibitor tipifarnib in children and young adults wirh neurofibromatosis type1 and progressive plexiform neurofibromas. Neuro Oncol. 2014;16:707\u201318.","journal-title":"Neuro Oncol"},{"key":"8298_CR19","doi-asserted-by":"publisher","first-page":"4581","DOI":"10.1182\/bloodadvances.2024012806","volume":"8","author":"T Witzig","year":"2024","unstructured":"Witzig T, Sokol L, Kim WS, de la Cruz Vincente F, Garcia-Sancho AM, et al. Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed\/refractory peripheral T-cell lymphoma. Blood Adv. 2024;8:4581\u201392.","journal-title":"Blood Adv"},{"key":"8298_CR20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s10637-018-0662-1","volume":"37","author":"K Jazieh","year":"2019","unstructured":"Jazieh K, Molina J, Allred J, Yin J, reid J, et al. A phase-I study of the farnesyltransferase inhibitor tipifarnib in combination with the EGFR tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors. Invest New Drugs. 2019;37:307\u201314.","journal-title":"Invest New Drugs"},{"key":"8298_CR21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11060-017-2624-4","volume":"136","author":"PL Nghiemphu","year":"2018","unstructured":"Nghiemphu PL, Ebiana VA, Wen P, Gilbert M, abrey LE, et al. Phase I study of sorafenib and tipifarnib for current glioblastoma: NABTC 05\u2009\u2013\u200902. J Neurooncol. 2018;136:79\u201386.","journal-title":"J Neurooncol"},{"key":"8298_CR22","doi-asserted-by":"publisher","first-page":"14459","DOI":"10.1074\/jbc.272.22.14459","volume":"272","author":"DB Whyte","year":"1997","unstructured":"Whyte DB, Kirschmeier P, Hockenberry TN, et al. K- and N-RAS are geranylated in cells treated with farnesyltransferas inhibitors. J Biol Chem. 1997;272:14459\u201364.","journal-title":"J Biol Chem"},{"key":"8298_CR23","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1001\/jama.2018.3264","volume":"319","author":"Gordon","year":"2018","unstructured":"Gordon LB, Shappell H, Massaro J, et al. Association of lonafarnib treatment vs no treatment with mortality rate of patients with Hutchinson-Gilford progeria syndrome. JAMA. 2018;319:1687\u201393.","journal-title":"JAMA"},{"key":"8298_CR24","doi-asserted-by":"publisher","first-page":"100335","DOI":"10.1016\/j.gim.2022.11.003","volume":"25","author":"M Suzuki","year":"2023","unstructured":"Suzuki M, Jeng LJB, Chefo S, Wang Y, Price D, et al. FDA approval summary for lonafarnib (Zokinvy) for the treatment of Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies. Genet Med. 2023;25:100335.","journal-title":"Genet Med"},{"key":"8298_CR25","doi-asserted-by":"publisher","first-page":"105250","DOI":"10.1016\/j.antiviral.2022.105250","volume":"198","author":"ER Verrier","year":"2022","unstructured":"Verrier ER, Salvetti A, Pons C, Micheler M, Rivoir M, et al. Loss of hepatitis D virus infectivity upon farnesyltransferase inhibitor treatment associates with increased RNA editing rates revealed by a new RT-ddPCR method. Antiviral Res. 2022;198:105250.","journal-title":"Antiviral Res"},{"key":"8298_CR26","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/S1473-3099(15)00074-2","volume":"15","author":"C Koh","year":"2015","unstructured":"Koh C, Canini L, Dahari H, Zhao X, Uprichard SL, et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double blind placebo controlled phase 2A trial. Lancet Infect Dis. 2015;15:1167\u201374.","journal-title":"Lancet Infect Dis"},{"key":"8298_CR27","doi-asserted-by":"crossref","unstructured":"Yurdaydin C, Keskin O, Yurdcu E, Caliskan A, Onem S, et al. A phase 2 dose-finding study of lonafarnib and rotavir with or without interferon alpha for chronic delta hepatitis. Hepatology. 2022;5:1551\u201365.","DOI":"10.1002\/hep.32259"},{"key":"8298_CR28","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/s41467-024-45241-y","volume":"15","author":"SM Sake","year":"2024","unstructured":"Sake SM, Zhang X, Rajak MK, Urbanek-Quaning M, Carpentier A, et al. drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor. Nat Commun. 2024;15:1173.","journal-title":"Nat Commun"},{"key":"8298_CR29","doi-asserted-by":"crossref","unstructured":"Weber L, Mautner L, Hoyos M, Ehrhardt A, Baiker A, Bachman HS. Effect of farnesyltransferase inhibitors on SARS-Cov2. J Glob Antimicrob Res. 2023;32:166.","DOI":"10.1016\/j.jgar.2022.11.011"},{"key":"8298_CR30","doi-asserted-by":"publisher","first-page":"671722","DOI":"10.1007\/s12639-024-01687-x","volume":"48","author":"P Biswas","year":"2024","unstructured":"Biswas P, Roy R, Ghosh K, Nath D, Samadder A, Nandi S. To quest new targets of Plasmodium parasite and their potential inhibitors to combat antimalarial drug resistance. J Parasit Dis. 2024;48:671722.","journal-title":"J Parasit Dis"},{"key":"8298_CR31","doi-asserted-by":"publisher","first-page":"628283","DOI":"10.3389\/fmicb.2021.628283","volume":"30","author":"L Weber","year":"2021","unstructured":"Weber L, Hagermann A, Kaltenhauser J, Besser M, Rockefeller P, et al. Bacteria are new targets for inhibitors of human farnesyltransferase. Front Microbiol. 2021;30:628283.","journal-title":"Front Microbiol"},{"key":"8298_CR32","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1200\/JCO.2012.42.9530","volume":"31","author":"N Thosani","year":"2013","unstructured":"Thosani N, Thosani SN, Kumar S, Nugent Z, Jimenez C, et al. reduced risk of colorectal cancer with the use of oral bisphosphonates: a systematic review and meta-analysis. J Clin Oncol. 2013;31:623\u201330.","journal-title":"J Clin Oncol"},{"key":"8298_CR33","doi-asserted-by":"publisher","first-page":"79503","DOI":"10.18632\/oncotarget.12806","volume":"7","author":"I Kenessey","year":"2016","unstructured":"Kenessey I, Koi K, Horv\u00e1th O, Cserepes M, Moln\u00e1r D, et al. KRAS-mutation status dependent effects of zoledronic acid in human non-small cell lung cancer preclinical models. Oncotarget. 2016;7:79503\u201314.","journal-title":"Oncotarget"},{"key":"8298_CR34","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1007\/s12253-019-00789-9","volume":"26","author":"M Baranyi","year":"2020","unstructured":"Baranyi M, Rittler D, Molnar E, Shirasawa S, Jalsewsky I, et al. Next generation lipophillic bisphosphonate shows antitumor effects in colorectal cancer in vitro and in vivo. Pathol Oncol Res. 2020;26:1957\u201369.","journal-title":"Pathol Oncol Res"},{"key":"8298_CR35","doi-asserted-by":"crossref","unstructured":"Radeczky P, Medgyesfalvi Z, L\u00e1szl\u00f3 V, Fillinger J, Moldvay J, et al. The effects of bisphosphonate and radiation therapy in bone-metastatic lung adenocarcinoma: the impact of KRAS mutation. Transl Lung Cancer Res. 2021;10:675\u201384.","DOI":"10.21037\/tlcr-20-754"},{"key":"8298_CR36","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ygyno.2014.07.094","volume":"135","author":"MD Trietsch","year":"2014","unstructured":"Trietsch MD, Spaans VM, terHaar NT, Osse EM, Peters AAW, et al. CDKN2A(p16) and HRAS are frequently mutated in vulvar squamous cell carcinoma. Gynecol Oncol. 2014;135:149\u201355.","journal-title":"Gynecol Oncol"},{"key":"8298_CR37","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41525-021-00226-4","volume":"6","author":"D Chang","year":"2021","unstructured":"Chang D, Shain AH. The landscape of driver mutations in cutaneous squamous cell carcinoma. NPJ Genomic Med. 2021;6:61.","journal-title":"NPJ Genomic Med"},{"key":"8298_CR38","doi-asserted-by":"publisher","first-page":"4276","DOI":"10.1172\/JCI128227","volume":"129","author":"AS Ho","year":"2019","unstructured":"Ho AS, Ochoa A, Jayakumaran G, Zehir A, Mayo CV, et al. Genetic hallmarks of recurrent\/metastatic adenoid cystic carcinoma. J Clin Invest. 2019;129:4276\u201389.","journal-title":"J Clin Invest"},{"key":"8298_CR39","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1158\/2159-8290.CD-13-0639","volume":"4","author":"JF Shern","year":"2014","unstructured":"Shern JF, Chen L, Chmieleck J, Wei JS, Patidar R, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 2014;4:216\u201331.","journal-title":"Cancer Discov"},{"key":"8298_CR40","doi-asserted-by":"publisher","first-page":"e2200211","DOI":"10.1200\/PO.22.00211","volume":"7","author":"N Coleman","year":"2023","unstructured":"Coleman N, Marcelo KL, Hopkins JF, Khan NI, Du R, et al. HRAS mutation define a distinct subgroup in head and neck squamous cell carcinoma. JCO Pres Oncol. 2023;7:e2200211.","journal-title":"JCO Pres Oncol"},{"key":"8298_CR41","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1200\/JCO.20.02903","volume":"39","author":"AL Ho","year":"2021","unstructured":"Ho AL, Brana I, Haddad R, Baumann J, Bible K, et al. Tipifarnib in head and neck squamous cell carcinoma with HRAS mutations. J Clin Oncol. 2021;39:1856\u201364.","journal-title":"J Clin Oncol"},{"key":"8298_CR42","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1158\/0008-5472.CAN-23-0282","volume":"83","author":"AE Smith","year":"2023","unstructured":"Smith AE, Chan S, Wang Z, McCloskey A, Reilly Q, et al. Tipifarnib potentiates the antitumor effects of PI3Ka inhibition in PIK3CA- and HRAS-dysregulated HNSCC via convergent inhibition of mTOR activity. Cancer Res. 2023;83:3252\u201363.","journal-title":"Cancer Res"},{"key":"8298_CR43","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1097\/PAS.0000000000002171","volume":"48","author":"K Kitahama","year":"2024","unstructured":"Kitahama K, Shigematsu Y, Amori G, Sugawara E, Yonese J, et al. RAS family gene mutations, clinicopathological features and spread patterns of inverted urothelial papilloma of the bladder. Am J Surg Pathol. 2024;48:458\u201364.","journal-title":"Am J Surg Pathol"},{"key":"8298_CR44","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.euo.2022.08.002","volume":"6","author":"JJ De Jong","year":"2023","unstructured":"De Jong JJ, Pijpers OM, van Kessel EM, boormans JL, et al. A urine-based genomic assay improves risk stratification for patimnets with high-risk hematuria stratified according tot he American Urological Association Guidelines. Eur Urol Oncol. 2023;6:183\u20139.","journal-title":"Eur Urol Oncol"},{"key":"8298_CR45","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/cas.16025","volume":"115","author":"D Tamura","year":"2024","unstructured":"Tamura D, Abe M, Hiraki H, Sasaki N, Yashima-Abo A, et al. Postoperative recurrence detection using individualized circulating tumor DNA in upper tract urothelial carcinoma. Cancer Sci. 2024;115:529\u201339.","journal-title":"Cancer Sci"},{"key":"8298_CR46","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/cge.14111","volume":"101","author":"C Leoni","year":"2022","unstructured":"Leoni C, Paradiso FV, Fosch N, Tedesco M, Pierconti F, et al. Prevalence of bladder cancer in Costello syndrome: new insights to drive clinical decision-making. Clin Genet. 2022;101:454\u20138.","journal-title":"Clin Genet"},{"key":"8298_CR47","doi-asserted-by":"crossref","unstructured":"Rosenberg JE, von der Maase H, Seigne JD, Mandial J, Vaughn DJ, et al. A phase II trial of R115777 an oral farnesyltransferase inhibitor in patients with advanced urothelial tract transitional cell carcinoma. Cancer. 2005;103:2035\u201341.","DOI":"10.1002\/cncr.21023"},{"key":"8298_CR48","doi-asserted-by":"publisher","first-page":"5113","DOI":"10.1158\/1078-0432.CCR-20-1246","volume":"26","author":"HW Lee","year":"2020","unstructured":"Lee HW, Sa JK, Gualberto A, Scholz C, Sung HW, et al. A phase II trial of tipifarnib for patients with previously treated metastatic urothelial carcinoma harboring HRAS mutation. Clin Cancer Res. 2020;26:5113\u20139.","journal-title":"Clin Cancer Res"},{"key":"8298_CR49","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.1002\/cncr.33036","volume":"126","author":"GJ Hanna","year":"2020","unstructured":"Hanna GJ, Guenette JP, Chau NG, Sayehli CM, Wilhelm C, et al. Tipifarnib in recurrent metastatic HRAS-mutant salivary gland cancer. Cancer. 2020;126:3972\u201381.","journal-title":"Cancer"},{"key":"8298_CR50","doi-asserted-by":"crossref","unstructured":"Hanna GJ, Thomas J, Bruce JY, Patel MR, Sonpavde GP, et al. A phase-I study of the next-generation farnesyltransferase inhibitor (FTI) KO-2806 as monotherapy in advanced solid tumors. Ann Oncol. 2025;36:S2S641.","DOI":"10.1016\/j.annonc.2025.08.1550"},{"key":"8298_CR51","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s43018-023-00710-z","volume":"5","author":"AMG Elbatsh","year":"2024","unstructured":"Elbatsh AMG, Amin-Mansour A, Haberkorn A, Textor C, Ebel N, et al. INPP5A phosphatase is a synthetic lethal target in GNAG and GNA11-mutant melanomas. Nat Cancer. 2024;5:481\u201399.","journal-title":"Nat Cancer"},{"key":"8298_CR52","doi-asserted-by":"crossref","unstructured":"Nigam A, Krishnamoorthy GP, Chatila WK, Berman K, Saqcena M, et al. Cooperative genomic lesions in HRAS-mutant cancers predict resistance to farnesyltransferase inhibitors. Oncogene. 2024;43:2806\u201319.","DOI":"10.1038\/s41388-024-03095-0"},{"key":"8298_CR53","doi-asserted-by":"crossref","unstructured":"Untch BR, Dos Anjos V, Garcia-Rendueles MER, Knauf JA, Krishnamorthy GP, et al. Tipifarnib inhibits HRAS-driven dedifferentiated thyroid cancer. Cancer Res. 2018;78:4642\u201357.","DOI":"10.1158\/0008-5472.CAN-17-1925"},{"key":"8298_CR54","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","volume":"30","author":"A Singhal","year":"2024","unstructured":"Singhal A, Li BT, O\u2019Reilly EM. Targeting KRAS in cancer. Nat Med. 2024;30:969\u201383.","journal-title":"Nat Med"},{"key":"8298_CR55","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1158\/1538-7445.AM2023-1079","volume":"83\/S7","author":"HV Patel","year":"2023","unstructured":"Patel HV, Smith A, Chan S, Kessler L, Burrows F, Malik S. Combination of tipifarnib with KRASG12C inhibitors to treat KRASG12C mutant NSCLC. Cancer Res. 2023;83\/S7:1079.","journal-title":"Cancer Res"},{"key":"8298_CR56","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/s41416-024-02586-x","volume":"130","author":"M Baranyi","year":"2024","unstructured":"Baranyi M, Moln\u00e1r E, Heged\u0171s L, G\u00e1briel Z, Pet\u00e9nyi FG, et al. Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors. Br J Cancer. 2024;130:1059\u201372.","journal-title":"Br J Cancer"},{"key":"8298_CR57","doi-asserted-by":"publisher","DOI":"10.1158\/00008-5472.CAN-25-2764","author":"HV Patel","year":"2026","unstructured":"Patel HV, Smith AE, Chan S, Gasendo JG, Jombik A, et al. The farnesyltransferase inhibitor darlifarnib (KO-2906) re-sensitizes relapsing tumors to RAS inhibition. Cancer Res. 2026. https:\/\/doi.org\/10.1158\/00008-5472.CAN-25-2764.","journal-title":"Cancer Res"},{"key":"8298_CR58","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jtho.2024.11.022","volume":"20","author":"A Kazi","year":"2024","unstructured":"Kazi A, Vasiyani H, Ghosh D, Bandyopadhyay D, Shah RD, et al. FGTI-2734 inhibits ERK reactivation to overcome sotorasib resistance in KRAS G12C lung cancer. J Thor Oncol. 2024;20:331\u201344.","journal-title":"J Thor Oncol"},{"key":"8298_CR59","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.trecan.2023.07.010","volume":"9","author":"MN Zeissig","year":"2023","unstructured":"Zeissig MN, Ashwood LM, Kondrashova O, Sutherland KD. Next butter up! Targeting cancers with KRASG12D inhibitors. Trends Cancer. 2023;9:955\u201367.","journal-title":"Trends Cancer"},{"key":"8298_CR60","doi-asserted-by":"crossref","unstructured":"Moln\u00e1r E, Baranyi M, Szigeti K, Heged\u0171s B, Bord\u00e1s F, et al. Combination of farnesyl-transferase inhibition with KRASG12D targeting breaks down therapeutic resistance in pancreatic cancer. Pathol Oncol Res. 2024;30:1611948.","DOI":"10.3389\/pore.2024.1611948"},{"key":"8298_CR61","doi-asserted-by":"publisher","first-page":"116255","DOI":"10.1016\/j.ejca.2026.116255","volume":"236","author":"D Ghosh","year":"2026","unstructured":"Ghosh D, Kazi A, Kumar H, Vasiyani K, Vudata V, et al. FGTI-2734 prevents ERK-mediated resistance and enhances MRTX1133 efficacy in KRAS G12D pancreatic cancer. Eur J Cancer. 2026;236:116255.","journal-title":"Eur J Cancer"},{"key":"8298_CR62","doi-asserted-by":"crossref","unstructured":"Filis P, Salgkarnis D, Matikas A, Zerdos I. Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236. Drug Discov Today. 2025;30:104250.","DOI":"10.1016\/j.drudis.2024.104250"},{"key":"8298_CR63","unstructured":"Timar J, Heged\u00fcs B, Baranyi M. Farnesyltransferase inhibitors potentiate antitumoral effects of mutant KRAS inhibitors in preclinical models of cancer. The Fifth RAS initiative symposium. Frederick. MD, Oct 8\u201310,2024, P24\/D2."},{"key":"8298_CR64","doi-asserted-by":"publisher","first-page":"5345","DOI":"10.1038\/s41467-024-49360-4","volume":"15","author":"S Figarol","year":"2024","unstructured":"Figarol S, Delahaye C, Gence R, Doussine A, Cerapio JP, et al. Farnesyltransferase inhibition overcomes oncogene-addicted non-small cell lung cancer adaptive resistance to target therapies. Nat Commun. 2024;15:5345.","journal-title":"Nat Commun"},{"key":"8298_CR65","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1158\/0008-5472.CAN-23-0282","volume":"83","author":"AE Smith","year":"2023","unstructured":"Smith AE, Chan S, Wang Z, McCloskey A, Reilly Q, et al. Tipifarnib potentiates the antitumor effects of PI3Ka inhibition in PIK3CA- and HRAS-dysregulated HNSCC via convergent inhibition of mTOR activity. Cancer Res. 2023;83:3252\u201363.","journal-title":"Cancer Res"},{"key":"8298_CR66","doi-asserted-by":"publisher","unstructured":"Gasendo JG, Chan S, Patel HV, Smith A, Kessler L, et al. Farnesyltransferase inhibitor KO-2806 (darlifarnib) enhances the antitumor activity of tyrosine kinase inhibitors in RCC. Mol Cancer Ther. 2026. https:\/\/doi.org\/10.1158\/1533-7163.MCT-25-0449.","DOI":"10.1158\/1533-7163.MCT-25-0449"},{"key":"8298_CR67","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.1038\/s41467-024-47771-x","volume":"15","author":"P Pucci","year":"2024","unstructured":"Pucci P, Lee LC, Han M, Mathews JD, Jahangiri L, et al. Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma. Nat Commun. 2024;15:3422.","journal-title":"Nat Commun"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08298-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08298-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08298-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:06:59Z","timestamp":1785521219000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08298-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8298"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08298-5","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"23 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that MB, JT, and BH filed an international patent for the combinational treatment of KRAS inhibitors and farnesyl-transferase inhibitors of KRAS mutant cancers (patent number: EP4426303B1).","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"974"}}